ASTH

Over the past six months, Astrana Health's stock experienced a 21.53% decline in the last three months, despite a 48.37% year-to-date gain and a 28.03% one-year increase, closing at $36.81 on October 5, 2026. Shares rose 4.7% to $37.55 on October 9, 2026, following a reaffirmed 'Buy' rating from Freedom Capital Markets with a $50 target, despite a mixed Q2 report. However, a 'material' cybersecurity incident and data breach at a subsidiary caused a 5.5% stock drop in late September 2026. A newly announced shareholder fraud investigation, concerns about an aggressive acquisition strategy, a $545 million related-party loan, and exposure to 2027 Medicare regulatory changes have also contributed to a volatile year, resulting in a nearly 20% decline over a 90-day period. Despite these challenges, some analysts view the shares as undervalued, with intrinsic value estimates ranging from $50 to $66. The Q2 2026 earnings report showed revenue up 48.5% year-over-year to $972.5 million, slightly missing expectations, while adjusted EPS beat analyst estimates by 9.6%. The company has consistently beaten earnings estimates, with an average surprise of 92.10% over the last two quarters.